<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02570633</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 28236814.3.0000.5149</org_study_id>
    <nct_id>NCT02570633</nct_id>
  </id_info>
  <brief_title>Ginger Capsules for the Prophylactic Treatment of Migraine</brief_title>
  <official_title>Double-blind Placebo-controlled Clinical Trial of Ginger (Zingiber Officinale) in Prophylactic Migraine Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federal University of Minas Gerais</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federal University of Minas Gerais</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to evaluate ginger efficacy as an prophylactic treatment
      of migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with the diagnosis of migraine according to the IHS criteria will receive capsules
      of 200 mg of ginger extract (5% active ingredient) or placebo (cellulose) to be taken three
      times a day for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the frequency of migraine attacks.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Frequency of migraine attacks will be assessed by headache diary.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in migraine impact in the last month.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Migraine impact will be assessed by HIT-6.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in migraine impact in the last three months.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Migraine impact will be assessed by MIDAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the serum levels of biomarkers.</measure>
    <time_frame>12 weeks</time_frame>
    <description>Biomarkers: inflammatory mediators and neurotrophic factors</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Resting Energy Expenditure</measure>
    <time_frame>4, 8 and 12 weeks</time_frame>
    <description>Resting Energy Expenditure will be assessed by calorimeter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Extract of ginger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cellulose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Extract of ginger</intervention_name>
    <description>Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.</description>
    <arm_group_label>Extract of ginger</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Cellulose</intervention_name>
    <description>Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.</description>
    <arm_group_label>Cellulose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 18 and 60 years old;

          -  Migraine diagnosis;

          -  Agree to sign the informed consent.

        Exclusion Criteria:

          -  Patients with headaches not characterized as migraine;

          -  Pregnant or lactating women;

          -  Fertile and sexually active women who do not use contraception;

          -  Abuse of painkillers, alcohol or other drugs;

          -  People with hypersensitivity to ginger compounds;

          -  People with severe neurological diseases (e.g. epilepsy)

          -  People in use of anticoagulant drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adaliene VM Ferreira, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laís B Martins, Ma</last_name>
    <role>Study Chair</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antônio L Teixeira, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Minas Gerais</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ambulatório Bias Fortes</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30130-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>March 12, 2020</last_update_submitted>
  <last_update_submitted_qc>March 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federal University of Minas Gerais</investigator_affiliation>
    <investigator_full_name>Antonio L Teixeira Jr</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Ginger</keyword>
  <keyword>Prophylactic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

